Quince Therapeutics, Inc. Operating Cash Flow
Quince Therapeutics, Inc. (QNCX) reported Operating Cash Flow of -$26.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$18.89M.
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$7.63M.
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$10.48M.
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.93M.
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$41.42M.
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$31.90M.
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$18.29M.
- Quince Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$44.04M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$26.51M 10-Q · filed 2026-08-14 | -$36.99M derived: sum of 3 quarters · filed 2026-08-14 | -$46.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$7.63M 10-Q · filed 2026-05-11 | -$18.11M derived: sum of 2 quarters · filed 2026-05-11 | -$28.04M derived: sum of 3 quarters · filed 2026-05-11 | -$39.45M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$20.41M derived: sum of 2 quarters · filed 2026-04-10 | -$31.82M derived: sum of 3 quarters · filed 2026-08-14 | -$41.42M 10-K · filed 2026-04-10 |
| 2025-09-30 | -$9.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$21.34M derived: sum of 2 quarters · filed 2026-08-14 | -$30.94M 10-Q · filed 2025-11-12 | -$38.50M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$11.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$21.02M 10-Q · filed 2026-08-14 | -$28.57M derived: sum of 3 quarters · filed 2026-08-14 | -$35.83M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$9.60M 10-Q · filed 2026-05-11 | -$17.15M derived: sum of 2 quarters · filed 2026-05-11 | -$24.41M derived: sum of 3 quarters · filed 2026-05-11 | -$33.15M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$14.81M derived: sum of 2 quarters · filed 2026-04-10 | -$23.55M derived: sum of 3 quarters · filed 2026-04-10 | -$31.90M 10-K · filed 2026-04-10 |
| 2024-09-30 | -$7.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$16.00M derived: sum of 2 quarters · filed 2025-11-12 | -$24.35M 10-Q · filed 2025-11-12 | -$30.43M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$8.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$17.09M 10-Q · filed 2025-08-11 | -$23.17M derived: sum of 3 quarters · filed 2025-08-11 | -$27.99M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$8.35M 10-Q · filed 2025-05-13 | -$14.43M derived: sum of 2 quarters · filed 2025-05-13 | -$19.25M derived: sum of 3 quarters · filed 2025-05-13 | -$23.08M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$10.90M derived: sum of 2 quarters · filed 2025-03-24 | -$14.72M derived: sum of 3 quarters · filed 2025-03-24 | -$18.29M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$4.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$8.64M derived: sum of 2 quarters · filed 2024-11-13 | -$12.21M 10-Q · filed 2024-11-13 | -$18.05M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$3.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$7.40M 10-Q · filed 2024-08-13 | -$13.23M derived: sum of 3 quarters · filed 2024-08-13 | -$19.93M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$3.57M 10-Q · filed 2024-05-13 | -$9.40M derived: sum of 2 quarters · filed 2024-05-13 | -$16.10M derived: sum of 3 quarters · filed 2024-05-13 | -$31.52M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$12.53M derived: sum of 2 quarters · filed 2024-04-01 | -$27.95M derived: sum of 3 quarters · filed 2024-04-01 | -$44.04M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$22.11M derived: sum of 2 quarters · filed 2023-11-14 | -$38.20M 10-Q · filed 2023-11-14 | -$52.62M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$15.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$31.51M 10-Q · filed 2023-08-03 | -$45.92M derived: sum of 3 quarters · filed 2023-08-03 | -$63.27M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$16.09M 10-Q · filed 2023-05-15 | -$30.51M derived: sum of 2 quarters · filed 2023-05-15 | -$47.85M derived: sum of 3 quarters · filed 2023-05-15 | -$65.41M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$14.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$31.76M derived: sum of 2 quarters · filed 2023-03-15 | -$49.32M derived: sum of 3 quarters · filed 2023-03-15 | -$62.93M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$17.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$34.90M derived: sum of 2 quarters · filed 2022-11-09 | -$48.51M 10-Q · filed 2022-11-09 | -$61.79M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$17.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$31.17M 10-Q · filed 2022-08-09 | -$44.45M derived: sum of 3 quarters · filed 2022-08-09 | -$56.82M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$13.61M 10-Q · filed 2022-05-10 | -$26.89M derived: sum of 2 quarters · filed 2022-05-10 | -$39.26M derived: sum of 3 quarters · filed 2022-05-10 | -$53.65M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$13.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$25.65M derived: sum of 2 quarters · filed 2022-03-01 | -$40.04M derived: sum of 3 quarters · filed 2022-03-01 | -$50.82M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$12.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | -$26.76M derived: sum of 2 quarters · filed 2021-10-29 | -$37.54M 10-Q · filed 2021-10-29 | -$48.49M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$14.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$25.17M 10-Q · filed 2021-08-06 | -$36.12M derived: sum of 3 quarters · filed 2022-03-01 | -$44.92M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$10.78M 10-Q · filed 2021-05-06 | -$21.73M derived: sum of 2 quarters · filed 2022-03-01 | -$30.52M derived: sum of 3 quarters · filed 2022-03-01 | -$36.84M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$10.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$19.75M derived: sum of 2 quarters · filed 2022-03-01 | -$26.06M derived: sum of 3 quarters · filed 2022-03-01 | -$33.28M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$8.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$15.11M derived: sum of 2 quarters · filed 2020-11-12 | -$22.33M 10-Q · filed 2020-11-12 | -$26.30M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$6.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$13.53M 10-Q · filed 2020-08-14 | -$17.50M derived: sum of 3 quarters · filed 2021-03-01 | -$19.43M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$7.22M 10-Q · filed 2020-05-12 | -$11.19M derived: sum of 2 quarters · filed 2021-03-01 | -$13.11M derived: sum of 3 quarters · filed 2021-03-01 | -$15.73M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$5.90M derived: sum of 2 quarters · filed 2021-03-01 | -$8.52M derived: sum of 3 quarters · filed 2021-03-01 | -$11.70M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$4.54M derived: sum of 2 quarters · filed 2019-11-12 | -$7.72M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$5.80M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | -$3.18M 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |